| Name | Title | Contact Details |
|---|
At Outpost, we are committed to developing novel therapeutics for the treatment of gastrointestinal and urologic disorders. The company`s lead clinical-stage product candidate is in development for the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS). Located in Indianapolis and London, Outpost is a private company launched in 2016 with a $61 million Series A venture capital financing from Frazier Healthcare Partners, Adams Street Partners, Novo Holdings A/S, Vivo Capital, and Takeda Ventures.
Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders.
BioSciConcepts is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Portage is a unique entity in the world of biotechnology, catalyzing R&D to produce more quality clinical programs and maximize potential returns.